Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.81 |
| ▸ | CCND1 | P24385 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989829 | 0.98 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL9703488 | 0.98 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL135070 | 0.94 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL1120445 | 0.86 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6258190 | 0.85 | CDK4 (0.73) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL28616424 | 0.84 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL20378423 | 0.82 | HTT (0.61) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL11366447 | 0.82 | CDK4 (1.00) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL8656866 | 0.81 | CDK4 (0.81) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL3477752 | 0.81 | CDK4 (0.81) | CDK4CCND1LMNAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1229082-A | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 1999-09-22 | — | — | CN | claimed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | claimed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| US-5990094-A | SEROTONIN N-ACETYLTRANSFERASE INHIBITORS WHICH CAN SERVE AS BIOLOGICAL TOOLS THAT HELP REVEAL BIOLOGICAL FUNCTIONS FOR MELATONIN AND PINEAL SEROTONIN IN VIVO; ACETYL-COA N-ACETYL TRYPTAMINE DERIVATIVES OF GIVEN STRUCTURE | THE ROCKEFELLER UNIVERSITY (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | CDK4 455/4885CCND1 1536/4885LMNA 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.